The estimated Net Worth of Jonathan White is at least $2.54 million dollars as of 26 October 2015. Jonathan White owns over 319 units of Haemonetics stock worth over $2,210,232 and over the last 16 years Jonathan sold HAE stock worth over $329,244.
Jonathan has made over 14 trades of the Haemonetics stock since 2009, according to the Form 4 filled with the SEC. Most recently Jonathan sold 319 units of HAE stock worth $10,249 on 26 October 2015.
The largest trade Jonathan's ever made was selling 3,000 units of Haemonetics stock on 26 February 2013 worth over $122,070. On average, Jonathan trades about 374 units every 74 days since 2009. As of 26 October 2015 Jonathan still owns at least 30,507 units of Haemonetics stock.
You can see the complete history of Jonathan White stock trades at the bottom of the page.
Jonathan's mailing address filed with the SEC is 400 WOOD ROAD, , BRAINTREE, MA, 02184.
Over the last 21 years, insiders at Haemonetics have traded over $82,114,016 worth of Haemonetics stock and bought 334,931 units worth $14,646,550 . The most active insiders traders include Paul Black, Robert E Abernathy et Brad Nutter. On average, Haemonetics executives and independent directors trade stock every 13 days with the average trade being worth of $539,753. The most recent stock trade was executed by Stewart W Strong on 26 July 2024, trading 4,312 units of HAE stock currently worth $393,039.
haemonetics is the blood management company. our comprehensive portfolio of integrated devices, information management, and consulting services offers blood management solutions for each facet of the blood management continuum. collectively they help improve patient care, ensure patient safety, and reduce costs for blood and plasma collectors, hospitals, and patients around the world. our mission we believe that through proper blood management, our products and services can help our commercial plasma and blood center customers optimize their collection processes. we seek to help ensure a continual supply of high-quality plasma for biopharmaceuticals and blood components for therapeutic use at optimal costs, along with better blood management processes. working with our hospital customers, we seek to prevent a blood transfusion to the patient who doesn’t need one, or, if a transfusion is necessary, to ensure the transfusion of the right blood product, at the right time, in the right
Haemonetics executives and other stock owners filed with the SEC include: